Alpha Cognition Inc. (ACOG) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help t
Alpha Cognition Inc. (ACOG) shares ended the last trading session 8.6% higher at $5.96. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 4.5% loss over the past four weeks.
Alpha Cognition’s stock price rally is largely tied to the renewed investor optimism around its pipeline progress and the growth and expansion of its Alzheimer’s drug Zunveyl. The company is advancing multiple post-marketing studies to strengthen the real-world profile of Zunveyl. Enrollment is ongoing in the BEACON study, while the planned CONVERGE and RESOLVE studies aim to generate additional data on cognition, behavior, dosing, and tolerability in Alzheimer’s patients, particularly in long-term care settings. These efforts are expected to support future regulatory discussions and improve physician and payer confidence.
This company is expected to post quarterly loss of $0.23 per share in its upcoming report, which represents a year-over-year change of -15%. Revenues are expected to be $4.88 million, up 66.4% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Alpha Cognition Inc., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ACOG going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Alpha Cognition Inc. is part of the Zacks Medical - Biomedical and Genetics industry. Caribou Biosciences, Inc. (CRBU), another stock in the same industry, closed the last trading session 4.7% higher at $1.99. CRBU has returned 8% in the past month.
Caribou Biosciences' consensus EPS estimate for the upcoming report has changed +7.6% over the past month to -$0.33. Compared to the company's year-ago EPS, this represents a change of +23.3%. Caribou Biosciences currently boasts a Zacks Rank of #2 (Buy).
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.
SeeWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Join 500,000+ readers who start their day with Quartz.
By subscribing, you agree to our Terms of Service and Privacy Policy.
